IL186293A0 - Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor - Google Patents

Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor

Info

Publication number
IL186293A0
IL186293A0 IL186293A IL18629307A IL186293A0 IL 186293 A0 IL186293 A0 IL 186293A0 IL 186293 A IL186293 A IL 186293A IL 18629307 A IL18629307 A IL 18629307A IL 186293 A0 IL186293 A0 IL 186293A0
Authority
IL
Israel
Prior art keywords
aag
prodrug
combination
multiple myeloma
proteasome inhibitor
Prior art date
Application number
IL186293A
Other languages
English (en)
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of IL186293A0 publication Critical patent/IL186293A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL186293A 2005-04-29 2007-09-25 Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor IL186293A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67655605P 2005-04-29 2005-04-29
US68623205P 2005-05-31 2005-05-31
US74919005P 2005-12-09 2005-12-09
PCT/US2006/016283 WO2006119032A1 (en) 2005-04-29 2006-04-26 Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor

Publications (1)

Publication Number Publication Date
IL186293A0 true IL186293A0 (en) 2008-01-20

Family

ID=37308288

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186293A IL186293A0 (en) 2005-04-29 2007-09-25 Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor

Country Status (10)

Country Link
US (1) US20060252740A1 (enExample)
EP (1) EP1874297A4 (enExample)
JP (1) JP2008539273A (enExample)
KR (1) KR20080007642A (enExample)
AU (1) AU2006242446A1 (enExample)
BR (1) BRPI0609861A2 (enExample)
CA (1) CA2604424A1 (enExample)
IL (1) IL186293A0 (enExample)
MX (1) MX2007013499A (enExample)
WO (1) WO2006119032A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
WO2006118953A2 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag of 17-ag of a prodrug of either
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CA2680161A1 (en) * 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US8672869B2 (en) * 2007-10-30 2014-03-18 Bellco S.R.L. Kit, system and method of treating myeloma patients
WO2009143290A2 (en) * 2008-05-20 2009-11-26 Cleveland Biolabs, Inc Inducing cell death by inhibiting adaptive heat shock response
ES2585114T3 (es) 2008-06-17 2016-10-03 Millennium Pharmaceuticals, Inc. Compuestos de ésteres boronato y composiciones farmacéuticas de los mismos
WO2010054381A2 (en) * 2008-11-10 2010-05-14 Mount Sinai School Of Medicine Of New York University Method of treating cancer with a combination of a proteasome inhibitor and salubrinal
AU2009347159B2 (en) * 2009-05-27 2015-09-03 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
CA2949517A1 (en) 2014-05-20 2015-11-26 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
WO2016205538A1 (en) * 2015-06-16 2016-12-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing hydrogen peroxide accumulation in cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
CA2132711C (en) * 1992-03-23 2005-02-08 Aquilar Rahman Liposome encapsulated paclitaxel and a method of using the same
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
AU2002243646B2 (en) * 2001-01-25 2006-06-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US6890917B2 (en) * 2001-03-30 2005-05-10 The United States Of America As Represented By The Department Of Health And Human Services Geldanamycin derivative and method of treating cancer using same
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US6887993B1 (en) * 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
SG171690A1 (en) * 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders

Also Published As

Publication number Publication date
MX2007013499A (es) 2008-01-24
WO2006119032A1 (en) 2006-11-09
KR20080007642A (ko) 2008-01-22
US20060252740A1 (en) 2006-11-09
BRPI0609861A2 (pt) 2010-05-11
CA2604424A1 (en) 2006-11-09
EP1874297A1 (en) 2008-01-09
EP1874297A4 (en) 2009-04-22
JP2008539273A (ja) 2008-11-13
AU2006242446A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
IL186293A0 (en) Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
PT1877232E (pt) Processo para o tratamento de superfícies de madeira
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
PL2402317T3 (pl) Inhibitor DGAT
ZA200900109B (en) Pyrrolotriazine kinase inhibitors
IL196070A0 (en) Prolyl hydroxylase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
EP2081437A4 (en) METHODS OF TREATING OR PREVENTING INFESTATION
GB0719170D0 (en) Bolt-tightening tool
IL195331A0 (en) Hsp90 inhibitor
EP1940397A4 (en) METHOD FOR TREATING HYPERTONIA
ZA200806489B (en) A method for determining the effectiveness of a treatment for preeclampsia
EP1963462A4 (en) CORROSION INHIBITOR
PL1843880T3 (pl) Sposób obróbki drewna
EP1890690A4 (en) MAO-B INHIBITORS FOR TREATING OBESITY
IL186292A0 (en) Method of treating multiple myeloma using 17-aag of 17-ag of a prodrug of either
ZA200709150B (en) Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
SG115849A1 (en) Corrosion inhibition method
EP1938672A4 (en) PROCESS FOR PLASMA BORING
GB0421356D0 (en) Inhibitors
GB0509777D0 (en) Process for treating waste
GB0608357D0 (en) Method for treating effluent
EP1942101A4 (en) INHIBITOR OF -SECRETASE
PL2009121T3 (pl) Sposób przetwarzania odpadów
ZA200709153B (en) Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either